1. Severe congenital ichthyosiform dermatosis in CHIME syndrome successfully treated with ixekizumab.
- Author
-
Flowers LE, Dyer JA, and Eisenstein KA
- Subjects
- Humans, Heart Defects, Congenital complications, Heart Defects, Congenital drug therapy, Ichthyosiform Erythroderma, Congenital drug therapy, Ichthyosiform Erythroderma, Congenital complications, Ichthyosiform Erythroderma, Congenital genetics, Intellectual Disability drug therapy, Intellectual Disability complications, Male, Dermatologic Agents therapeutic use, Interleukin-17 antagonists & inhibitors, Female, Antibodies, Monoclonal, Humanized therapeutic use
- Abstract
Coloboma, congenital heart disease, ichthyosiform dermatosis, intellectual disability, conductive hearing loss, and epilepsy (CHIME) syndrome is a rare autosomal recessive neuroectodermal disorder caused by PIGL gene mutations. There is emerging literature to support the use of interleukin-17 (IL-17) antagonists in the treatment of certain ichthyosiform dermatoses. Here, we report a case of severe ichthyosiform dermatosis in a child with CHIME syndrome who was recalcitrant to multiple topical medications and dupilumab. This is the first reported case of successful treatment of congenital ichthyosiform dermatosis in a CHIME syndrome patient with ixekizumab, an IL-17A antagonist., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF